Delivering quality therapy through generations
Search
 
  • Magyar
  • Русский
  • GR worldwide:
Skip Navigation Links
Printable version
Illustration 
Illustration 
Our products 
Richter is considered to be a branded generic pharmaceutical manufacturer. Whilst the dominant part of its turnover originates from generic drugs the Group also manufactures and markets the steroid based pharmaceuticals which represent a special, higher margin group of products. The separate section on Female healthcare describes our gynaecological products in details. Over the last decade this niche portfolio has contributed substantially to both the increase of sales and relatively high margins achieved by the Group.

   

Richter also markets as part of its portfolio original products and continues to carry out intensive research activities on diseases of the central nervous system. It is management’s opinion that it is important for the longer term success of the Group that it continues to research own developed compounds.

Gedeon Richter is a regional mid-sized pharma company with a vertically integrated structure. This is based on a good market position with geographic and therapeutic niches supported by continuous enhancement of supply of specialties partly via licensing agreements. Licensing-in is becoming an increasingly important route for the Group to renew its product portfolio. This is accomplished partly as an expansion of our existing generic product line and partly via providing high added value products either in the field of female healthcare or with original features.

Richter’s management continues to endeavour to provide greater focus and improved shape to the product portfolio. With this background it is understandable that most of the top ten products in 2008 originate from the three largest therapeutic categories. Gynaecological, cardiovascular and central nervous system products together generated 67 percent of total pharmaceutical sales.  Central nervous system related drugs contributed altogether 13 percent of total pharmaceutical sales.

After a slight contraction in 2007, cardiovascular drugs again produced an above average sales growth in 2008, accounting for 23 percent of total pharmaceutical sales. 

Gastrointestinal products represented 5 percent of total pharmaceutical sales.

Muscle relaxant drugs amounted to 5 percent of the total pharmaceutical revenue of the Group in 2008, following a substantial year on year increase.

The sales of antifungal products declined in 2008.

In line with the Group’s strategy the product portfolio has been successfully enhanced. This focus continues through withdrawing low volume and low margin products and introducing new products with improved profit potential. Progress by the Group in launching new products continued in 2008. 

Gynaecological products

Cardiovascular products

Medicines that act on the central nervous system

Gastroenterological products

OTC – Over the Counter Medicines

Antibiotics

Antimicotics

Medicines for treatment of the motor organs

PRICE BOX
BSE 2010.03.10. 09:58
41 600 HUF - 0.24%